List of Excipients in Branded Drug CELEBREX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
PFIZER LABORATORIES DIV PFIZER INC	CELEBREX	celecoxib	0025-1515	CROSCARMELLOSE SODIUM
PFIZER LABORATORIES DIV PFIZER INC	CELEBREX	celecoxib	0025-1515	GELATIN
PFIZER LABORATORIES DIV PFIZER INC	CELEBREX	celecoxib	0025-1515	LACTOSE MONOHYDRATE

CELEBREX Excipient Strategy and Commercial Opportunities for Celecoxib

Last updated: August 13, 2026

CELEBREX (celecoxib) is a mature oral NSAID with an open generic market, no biosimilar pathway, and limited remaining exclusivity protection. Its commercial excipient opportunity is not based on protecting the original capsule. It is based on improving celecoxib’s aqueous solubility, food-effect profile, dose flexibility, tolerability, and delivery format.

The reference product uses a conventional hard-gelatin capsule with a relatively simple excipient system. The strongest development opportunities are amorphous solid dispersions, lipid-based formulations, nanosized celecoxib, orally disintegrating or sprinkle products, and lower-excipient formulations for patients with lactose or surfactant sensitivities.

What is CELEBREX and how does its formulation work?

CELEBREX contains celecoxib, a selective cyclooxygenase-2 inhibitor approved for osteoarthritis, rheumatoid arthritis, acute pain, ankylosing spondylitis, and primary dysmenorrhea. The product is supplied as 50 mg, 100 mg, 200 mg, and 400 mg capsules. The 400 mg strength is generally used for acute treatment or loading rather than routine chronic dosing.[1]

Celecoxib has low aqueous solubility and high lipophilicity. These properties make dissolution and gastrointestinal absorption important formulation variables. Food increases celecoxib exposure and delays the time to maximum plasma concentration. The prescribing information recommends administration with food for certain dosing regimens, particularly at higher doses.[1]

The reference product uses an immediate-release capsule. Its core inactive ingredients include:

Formulation component	Function
Lactose monohydrate	Diluent and capsule-fill bulking agent
Sodium lauryl sulfate	Wetting agent and surfactant
Povidone	Binder and processing aid
Croscarmellose sodium	Disintegrant
Magnesium stearate	Lubricant
Gelatin	Capsule shell
Titanium dioxide	Opacifier and colorant
Edible inks	Product identification

The formulation is technically conventional. Its commercial importance lies in how the excipient blend manages a poorly water-soluble active ingredient while maintaining rapid capsule disintegration and acceptable bioavailability.[1]

What excipient strategy does the CELEBREX capsule use?

The original CELEBREX excipient strategy combines wetting, disintegration, binding, and lubrication rather than using a high-performance solubility-enhancement platform.

Surfactant strategy

Sodium lauryl sulfate improves wetting of hydrophobic celecoxib particles. This is important because celecoxib does not readily disperse in gastrointestinal fluid. The surfactant may help expose drug surface area to the dissolution medium, but it can create formulation and tolerability constraints at higher concentrations.

Potential development issues include:

• Variable wetting after scale-up.
• Interaction with hydrophobic lubricants.
• Sensitivity to particle size and mixing order.
• Possible gastrointestinal irritation at excessive levels.
• Restrictions for products marketed toward patients with excipient sensitivities.

Disintegrant strategy

Croscarmellose sodium promotes capsule-fill breakup after shell rupture. It does not independently solve celecoxib’s low solubility. A product can disintegrate rapidly while still showing slow or incomplete dissolution if the active remains crystalline and poorly wetted.

Binder and lubricant strategy

Povidone supports granulation and powder cohesion. Magnesium stearate improves manufacturing flow and ejection, but excessive lubrication can reduce wetting and slow dissolution. This is a standard risk in capsule and tablet development involving poorly soluble actives.

Capsule-shell strategy

Gelatin supports rapid release and broad manufacturing familiarity. HPMC capsules could support vegetarian, halal, kosher, or low-moisture positioning, but a shell substitution can affect moisture transfer, shell rupture, dissolution, and stability. A material change would require comparative dissolution and bioequivalence work.

Which excipient platforms can improve celecoxib performance?

The most relevant platforms are those that increase apparent solubility or reduce dependence on food.

Amorphous solid dispersions

Amorphous solid dispersions can increase dissolution by converting crystalline celecoxib into a higher-energy amorphous form stabilized in a polymer matrix. Suitable polymer families may include:

• Hypromellose acetate succinate.
• Hypromellose.
• Polyvinylpyrrolidone.
• Copovidone.
• Soluplus-type graft copolymers.
• Polyethylene oxide-based systems.

The main risks are recrystallization, moisture sensitivity, residual solvent, high solid-state complexity, and scale-up control. A successful dispersion could support a lower-dose capsule, improved fasted-state performance, or a differentiated 505(b)(2) product if clinical advantages are demonstrated.

Lipid-based formulations

Self-emulsifying drug delivery systems and other lipid-based systems can increase dissolution of lipophilic celecoxib. Potential excipient classes include medium-chain triglycerides, mono- and diglycerides, nonionic surfactants, and cosolvents.

Commercial advantages may include:

• Reduced dependence on crystalline particle dissolution.
• Potentially improved exposure in the fasted state.
• Use in softgel or liquid-filled hard-capsule formats.
• Opportunity for a differentiated dosage form.

The risks include capsule compatibility, oxidation, leakage, fill-volume constraints, taste and handling issues, and changes in food interaction.

Nanocrystal or nanosuspension systems

Particle-size reduction can increase surface area and improve dissolution without changing the chemical identity of celecoxib. Stabilizers may include polymeric or surfactant systems such as hypromellose, povidone, poloxamers, or polysorbates.

This route is attractive for high-dose products because it can avoid the large excipient mass associated with some polymeric dispersions. The primary risks are aggregation, Ostwald ripening, physical instability, specialized milling or homogenization equipment, and a need to demonstrate consistent particle-size distribution.

Cyclodextrin complexes

Cyclodextrins can improve apparent solubility and may support liquid, oral-mucosal, or rapidly dispersible products. Their limitations include complexation efficiency, high excipient load, cost, and the need to establish that the complex remains stable through manufacturing and storage.

Micronized and co-crystal approaches

Micronization is a relatively low-cost improvement but may provide limited benefit if particle agglomeration occurs. Co-crystals can modify dissolution and manufacturability without changing the active pharmaceutical ingredient’s covalent structure. They introduce solid-state intellectual property and regulatory characterization requirements.

What formulations are protected by CELEBREX patents?

The original CELEBREX product was protected primarily by compound, formulation, and method-of-use patents associated with celecoxib and its clinical indications. Those protections have expired or no longer block ordinary generic manufacture in the United States.

Protection category	Commercial status
Celecoxib compound protection	Expired
Original immediate-release capsule protection	Expired or no longer commercially blocking
Osteoarthritis and rheumatoid arthritis methods	Expired
Acute pain and dysmenorrhea methods	Expired or generally available to generic applicants
New excipient-enabled formulation	Potentially protectable if novel and non-obvious
New dosing regimen	Potentially protectable if supported by clinical and legal evidence
Pediatric or alternate dosage form	Potentially protectable, subject to patentability and regulatory exclusivity

A new excipient system could generate formulation patent claims covering composition, particle size, solid state, dissolution profile, manufacturing process, or pharmacokinetic performance. Broad claims directed only to “celecoxib plus an excipient” would face substantial obviousness risk because celecoxib has been widely formulated and studied.

Stronger claims would generally require a defined technical feature, such as:

• A specific amorphous-to-crystalline ratio.
• A defined dissolution threshold under fasted-state conditions.
• A controlled particle-size distribution.
• A narrowly defined polymer or lipid ratio.
• A demonstrated reduction in food effect.
• A reproducible pharmacokinetic advantage.
• A stable dosage form with a specific storage profile.

When did CELEBREX lose exclusivity?

CELEBREX lost meaningful U.S. market exclusivity after the expiration of its core patent estate and the subsequent approval of generic celecoxib capsules. FDA-approved generic celecoxib products entered the market in 2014, including products from Teva and other manufacturers.[2]

The principal exclusivity facts are:

Event	Timing
FDA approval of CELEBREX NDA 020998	1998
Core patent and regulatory protection period	Largely expired by the mid-2010s
Generic celecoxib approvals	Began in 2014
Current reference-product position	Mature branded product with generic competition
Current biosimilar risk	None; celecoxib is a small molecule

FDA’s Orange Book remains the principal source for listed patents, approved strengths, therapeutic equivalence codes, and exclusivity information.[3] The original product’s commercial defense is therefore based more on brand recognition, supply reliability, and physician familiarity than on active patent barriers.

What is the Orange Book status of CELEBREX?

CELEBREX is an approved small-molecule drug listed in the FDA Orange Book. Generic celecoxib capsules have received therapeutic equivalence designations, including AB-rated products where the relevant reference and generic products satisfy FDA bioequivalence requirements.[3]

The practical implications are:

• Generic applicants can rely on an ANDA pathway for conventional immediate-release capsules.
• An applicant must address any listed patents through certification, including Paragraph IV where applicable.
• The mature product has limited ability to block conventional generic entry through new use of the original excipients.
• A new dosage form or formulation may require a separate regulatory strategy, such as a 505(b)(2) application, depending on the extent of reliance on existing findings.

Which companies are challenging CELEBREX commercially?

Celecoxib competition comes from generic manufacturers rather than biosimilar developers. The market has included major generic companies such as Teva, Mylan or Viatris, Lupin, Amneal, and other ANDA holders over time. The precise active supplier set varies by strength, contract status, wholesaler channel, and FDA approval history.

The competitive structure includes:

Competitor type	Product strategy
Large generic manufacturers	Standard 50 mg, 100 mg, 200 mg, and 400 mg capsules
Regional generic suppliers	Select strengths and contract-market supply
Authorized or branded generic channels	Brand-equivalent positioning and supply continuity
Specialty developers	Potential differentiated formulations or alternate dosage forms
API suppliers	Celecoxib active ingredient and intermediate supply

No biosimilar competition applies because celecoxib is a chemically synthesized small molecule, not a biologic.

What Paragraph IV challenges affect CELEBREX?

Paragraph IV challenges were relevant during the transition from branded CELEBREX to generic celecoxib. Generic applicants used ANDA certifications against listed patents, and litigation risk depended on the specific patent, filing date, dosage strength, and proposed label.

Those disputes are no longer the principal commercial issue for standard celecoxib capsules. The current legal opportunity lies in protecting a new formulation or dosing approach, not in extending the original capsule’s expired protection.

A new formulation sponsor should expect scrutiny over:

• Whether the claims merely substitute routine excipients.
• Whether the claimed dissolution improvement was predictable.
• Whether the product has unexpected pharmacokinetic results.
• Whether the formulation creates a meaningful clinical benefit.
• Whether the patent claims cover an actual marketed product.
• Whether generic applicants can design around the claimed excipient ratios.

What commercial opportunities exist for celecoxib excipients?

The best opportunities are differentiated products that solve a measurable problem.

Fasted-state or reduced-food-effect celecoxib

A formulation that produces more consistent exposure without a high-fat meal could support a new product profile. The evidence would need to include fed and fasted pharmacokinetics, comparative dissolution, and clinical relevance.

Lower-dose high-bioavailability product

Improved dissolution could enable equivalent exposure at a lower nominal dose. This would be commercially attractive if it reduces adverse-event concerns or supports more precise titration. Dose reduction cannot be assumed from dissolution data alone; clinical exposure and efficacy must be demonstrated.

Pediatric or dysphagia-friendly dosage form

A multiparticulate, sprinkle, oral suspension, or orally disintegrating product could address patients who cannot swallow capsules. Taste masking, dose uniformity, sedimentation, physical stability, and handling would determine commercial feasibility.

Lactose-free or simplified excipient product

The reference capsule contains lactose monohydrate. A lactose-free product could target patients with lactose intolerance or customers seeking a simplified label. The commercial differentiation would be modest because many generic products may already use different excipient systems.

HPMC or specialty capsule format

A vegetarian or low-moisture capsule may create niche positioning for institutional, international, or specialty channels. The product would need meaningful quality or patient-use advantages to overcome the cost of switching from conventional gelatin capsules.

Compounding and hospital supply

Celecoxib liquid or dispersible presentations could support hospital, pediatric, and specialty pharmacy channels. Commercial scale would be smaller than the standard adult capsule market, but institutional customers may pay for reliable dosage-form availability.

Excipient supplier partnerships

Excipient manufacturers can pursue platform licensing or co-development with companies seeking improved celecoxib formulations. The strongest partner targets are suppliers with:

• Regulatory history for oral pharmaceutical use.
• Scale-up data for amorphous dispersions or nanoparticles.
• Drug-product analytical methods.
• Stability data for poorly soluble compounds.
• Existing manufacturing relationships with generic or specialty pharmaceutical companies.

How strong is the patent estate for a new celecoxib formulation?

The original CELEBREX patent estate is weak as a barrier to standard generic capsules because the core protections have expired. A new formulation estate can be stronger, but its value depends on claim scope and clinical differentiation.

Patent strategy	Relative strength
Celecoxib plus a routine filler	Low
Celecoxib plus a conventional disintegrant	Low
Defined amorphous dispersion with stability data	Moderate to high
Specific lipid system with improved fasted exposure	Moderate to high
Nanocrystal product with controlled particle size	Moderate
New capsule shell alone	Low to moderate
Pediatric dosage form with clinical utility	Moderate
New dosing regimen with demonstrated benefit	Moderate to high

Patent term should be planned from the earliest nonprovisional filing. A formulation patent filed after commercial development begins may provide meaningful protection through the 2040s, but only if the claims survive written-description, enablement, novelty, and obviousness challenges.

What regulatory pathway applies to a differentiated celecoxib product?

A conventional generic capsule generally proceeds under an ANDA. A materially different formulation may require a 505(b)(2) application if the sponsor relies partly on FDA findings for celecoxib but introduces a new dosage form, formulation, route, or pharmacokinetic profile.[4]

Potential regulatory requirements include:

• Comparative dissolution under multiple pH conditions.
• Fed and fasted pharmacokinetic studies.
• In vitro-in vivo correlation where relevant.
• Food-effect studies.
• Stability and solid-state characterization.
• Extractables and leachables testing for lipid or polymer systems.
• Dose uniformity for multiparticulates or suspensions.
• Clinical bridging where exposure or dosing differs materially.

A new formulation that claims lower gastrointestinal risk, lower cardiovascular risk, or improved clinical outcomes would require evidence beyond excipient performance.

What generic launch risks exist for a new CELEBREX formulation?

A differentiated product faces several launch risks even after patent grant:

1. Generic substitution may be limited if the product has no AB-rated equivalent.
2. Physicians may continue prescribing inexpensive standard celecoxib.
3. Payers may reject premium pricing for an established generic active.
4. FDA may require clinical studies that exceed initial development assumptions.
5. A generic manufacturer may design around narrow excipient claims.
6. The new product may improve dissolution without improving clinical outcomes.
7. Manufacturing costs may exceed the value of the commercial differentiation.
8. A high-performance excipient may create stability or supply-chain dependence.

The most defensible commercial proposition is a specific unmet-use case, such as a stable pediatric suspension or a demonstrated reduction in food-related exposure variability.

What revenue exposure does CELEBREX create for Pfizer and generic manufacturers?

Pfizer’s historical CELEBREX revenue was material during the branded exclusivity period. Current Pfizer public reporting generally does not isolate CELEBREX revenue as a separately disclosed growth asset, and the brand competes with multiple generic products.[5]

Revenue opportunity is therefore distributed across:

• Remaining branded prescription demand.
• Generic capsule volume.
• Specialty dosage forms.
• Contract manufacturing.
• Excipient and drug-delivery platform licensing.
• International markets with different substitution and reimbursement rules.

For an excipient developer, the addressable value is tied less to total historical CELEBREX sales than to whether a new dosage form can secure reimbursement, obtain differentiated labeling, and avoid direct therapeutic-equivalence substitution.

How does CELEBREX compare with other NSAID formulation opportunities?

Celecoxib is attractive for formulation work because its low solubility creates a clear technical problem. It is less attractive than a protected or rapidly growing product because standard generic pricing is low and payer substitution is strong.

Factor	Celecoxib	Ibuprofen	Naproxen
Solubility challenge	High	Moderate	Moderate
Generic competition	High	Very high	Very high
Formulation differentiation potential	High	Moderate	Moderate
Biosimilar exposure	None	None	None
Premium pricing potential	Limited without clinical benefit	Limited	Limited
505(b)(2) opportunity	Possible	Possible	Possible
Need for food-effect work	Important	Relevant	Relevant

Celecoxib may offer more technical room for excipient innovation than highly soluble or easily formulated NSAIDs. Its commercial challenge is proving that the improved formulation matters to patients, prescribers, or payers.

Key Takeaways

• CELEBREX uses a conventional capsule-fill system built around lactose, sodium lauryl sulfate, povidone, croscarmellose sodium, and magnesium stearate.
• Celecoxib’s low aqueous solubility creates the primary excipient-development opportunity.
• Amorphous solid dispersions, lipid systems, nanocrystals, and patient-friendly dosage forms are the strongest technical directions.
• Core CELEBREX exclusivity has expired, and generic celecoxib products entered the U.S. market in 2014.
• No biosimilar pathway applies.
• New formulation patents can be valuable, but routine excipient substitutions are vulnerable to obviousness challenges.
• A differentiated product will likely require an ANDA only if it remains therapeutically equivalent to the reference capsule. More substantial changes may require a 505(b)(2) application.
• The strongest commercial opportunities involve reduced food effect, pediatric or dysphagia-friendly delivery, lactose-free positioning, and demonstrable pharmacokinetic or usability benefits.
• Pfizer’s current CELEBREX revenue exposure is not separately disclosed in a way that supports a precise standalone estimate.
• The commercial case depends on clinical differentiation, reimbursement, and manufacturing scale, not on the original CELEBREX patent estate.

FAQs

Can celecoxib be reformulated as an oral suspension?

Yes. An oral suspension could target pediatric, geriatric, or dysphagia patients. Development would require dose uniformity, physical stability, taste masking, preservative control, and validated administration-device performance.

Can a new excipient combination obtain patent protection for celecoxib?

Yes, but the claims must recite a novel and non-obvious formulation or performance limitation. A simple substitution of lactose, povidone, or a standard disintegrant is unlikely to provide strong protection.

Does celecoxib have a biosimilar market?

No. Celecoxib is a small-molecule active ingredient regulated through generic-drug pathways, not the biologics licensing pathway used for biosimilars.

Would a celecoxib nanocrystal product automatically receive AB-rated generic status?

No. A nanocrystal or other materially different formulation may require a separate regulatory pathway and may not qualify for automatic therapeutic equivalence to the conventional CELEBREX capsule.

Which excipient opportunity is most commercially attractive for celecoxib?

A formulation that demonstrates a clinically relevant reduction in food-effect variability or enables a convenient pediatric or dysphagia-friendly dosage form has the clearest differentiation potential. A routine capsule-fill substitution has limited commercial value.

References

1. U.S. Food and Drug Administration. (2023). CELEBREX (celecoxib) capsules prescribing information. Pfizer Laboratories.

2. U.S. Food and Drug Administration. (2014). FDA approves first generic versions of Celebrex. https://www.fda.gov

3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). https://www.fda.gov

5. Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Pfizer Inc.